Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC011245 | Panoply™ Human PAFAH1B2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC011245 | Panoply™ Human PAFAH1B2 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD11753Z | Human PAFAH1B2 adenoviral particles | Inquiry |
| LV20879L | human PAFAH1B2 (NM_001184748) lentivirus particles | Inquiry |
| LV20880L | human PAFAH1B2 (NM_002572) lentivirus particles | Inquiry |
| LV20881L | human PAFAH1B2 (NM_001184747) lentivirus particles | Inquiry |
| LV20882L | human PAFAH1B2 (NM_001184746) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH370012 | shRNA set against Human PAFAH1B2 (NM_002572.3) | Inquiry |
| SHH370016 | shRNA set against Mouse PAFAH1B2 (NM_008775.3) | Inquiry |
| SHH370020 | shRNA set against Rat PAFAH1B2 (NM_022387.3) | Inquiry |
| SHR078018 | shRNA set against Rat Pafah1b2(NM_022387.3) | Inquiry |
| SHR078078 | shRNA set against Human PAFAH1B2(NM_002572.3) | Inquiry |
| SHR078132 | shRNA set against Mouse Pafah1b2(NM_008775.3) | Inquiry |
| SHW001542 | shRNA set against Chicken PAFAH1B2 (NM_001030911) | Inquiry |
| SHW011129 | shRNA set against Danio rerio PAFAH1B2 (NM_001082851) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR357491 | Human PAFAH1B2 ORF Clone(NM_001184748.1) | Inquiry |
| CDFH013609 | Human PAFAH1B2 cDNA Clone(NM_001184747.1) | Inquiry |
| CDFH013610 | Human PAFAH1B2 cDNA Clone(NM_001184746.1) | Inquiry |
| CDFH013611 | Human PAFAH1B2 cDNA Clone(NM_001184748.1) | Inquiry |
| CDFR011836 | Rat Pafah1b2 cDNA Clone(NM_022387.3) | Inquiry |
| MiUTR1H-07463 | PAFAH1B2 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-08866 | PAFAH1B2 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-05601 | PAFAH1B2 miRNA 3'UTR clone | Inquiry |
| CDCB163017 | Chicken PAFAH1B2 ORF Clone (NM_001030911) | Inquiry |
| CDCB172604 | Danio rerio PAFAH1B2 ORF Clone (NM_001082851) | Inquiry |
| CDCB189238 | Rabbit PAFAH1B2 ORF clone (XM_008260907.1) | Inquiry |
| CDCL145557 | Mouse Pafah1b2 ORF clone (NM_008775.3) | Inquiry |
| CDCR357487 | Human PAFAH1B2 ORF Clone(NM_001184746.1) | Inquiry |
| CDCR357490 | Human PAFAH1B2 ORF Clone(NM_001184747.1) | Inquiry |
| CDCR378995 | Rat Pafah1b2 ORF Clone(NM_022387.3) | Inquiry |
| CDCS409128 | Human PAFAH1B2 ORF Clone (BC000398) | Inquiry |
PAFAH1B2 and Cancer
Platelet-activating factor acetylhydrolase IB subunit beta (PAFAH1B2) is the catalytic subunit of platelet-activating factor acetylhydrolase (PAF-AH), a calculated molecular mass of 30 kDa. PAFAH1B2 has been shown to be overexpressed in some types of tumors such as breast cancer, lung cancer, and lymphoma. According to previous studies, platelet-activating factor acetylhydrolase IB subunit beta plays an important role in inflammation and anaphylaxis. In the recent study, PAFAH1B2 is overexpressed in pancreatic ductal adenocarcinoma (PDAC), resulting in epithelial emesenchymal transition (EMT), migration and invasion in vitro and metastasis in vivo, which is correlated inversely with patient survival. PAFAH1B2 overexpression in patients with PDAC is associated with the HIF1a. Based on these results, inhibition of PAFAH1B2 expression may be a new therapeutic strategy for the treatment of metastatic PDAC.
PAFAH1B2 can hydrolyze the lipid substances known as platelet activating factor (PAF), and RNAi-mediated knockdown of PAFAH1B2 does not alter PAF levels or PAF hydrolytic activity, indicating that the enzyme may possess alternate endogenous substrates. Rebecca A. Kohnz et al. recently discovered the oncogenic regulatory mechanisms for several cancer-relevant serine hydrolases. In their study, they found that pharmacological blockade of this enzyme impairs the pathogenicity across multiple different types of cancer including breast, ovarian, melanoma, and prostate cancer, while the pharmacological blockade of PAFAH1B2 causes unique changes in lipid metabolism, including heightened levels of tumor-suppressing lipids. They also observed that PAFAH1B2 is also highly expressed in multiple other human cancer cell lines (C8161, MUM2C melanoma, SKOV3 ovarian and MCF7 breast cancer cells) and inactivation of PAFAH1B2 leads to far wider alterations in lipid metabolism including increases in several tumor-suppressing lipids. These evidences suggest that PAFAH1B2 is important in maintaining cancer pathogenicity across a wide spectrum of cancer types.
Figure 1. PAFAH1B2 protein (predicted Homo sapiens).
References: